then vertex pharma shared a hand. of positive updates on the pipeline that caused the stock to jump higher. and we heard very different stories from dick's sporting goods and academy sports on the state of the business. so which is the better one to buy? i will give you my take. so stay with cramer. >> announcer: don't miss a second of "mad money." follow @jimcramer on x. have a question? tweet cramer. hashtag mad mentions. send jim an e-mail to madmoney@cnbc.com. or give us a call at 1-800-743-cnbc. missomhi? setng head to madmoney.cnbc.com. (sfx: stone wheel crafting) ♪ the biggest ideas inspire new ones. 30 years ago, state street created an etf that inspired the world to invest differently. it still does. what can you do with spy? ♪ that first time you take a step back. i made that. with your very own online store. i sold that. and you can manage it all in one place. i built this. and it was easy, with a partner that puts you first. godaddy. loving this pay bump in our allowance. wonder where mom and dad got the e

gc pete, they've had a few goo announcements with vertex an duets thought i. should see that i think gemini can only help but you know, it's funny it's the number three player here in g c p on cloud growth slowed down quite a bit here, potentially, the celebrated in three queue an you are looking to see tha restabilize before we can star talking about the benefits o jen a.i. for gcp overall >> for now, one of the things i can't tell us is who's gonna win the a.i. wars. [laughter] >> true. >> how smart is it, really >> not smart enough to trade yet. the fda just approved to breakthrough gene therapie that could help cure sickl cell disease coming up, we're going to hear from the ceo behind one of those treatments, power lunch, back into. >>> welcome back, everybody. a major medical milestone today, as the fda approves a drug t treat sickle cell anemia what makes it historic it's th first drug using a gene editin therapy called crispr. investors looking at the depending on the stocks, as silver news event as the company involved, it's verte down about 1%. crispr

in the case of vertex as product cash chevy. very they perform christopher past 9 gene editing where they're actually editing the genes that ordinarily helps regulate, give it to open production in our bodies. however, the therapy is expensive. links the n grueling. there are very few medical facilities authorized to perform it even in the us and fewer still in countries like nigeria, which has the largest number of sickle cell patients. so it is going to be a problem for us to be able to roll this out to where the vast majority of patients with this disease live, scientist believe the sickle cell treatment is only the 1st. so what will likely be a wave of gene editing therapies? for cancer, cystic fibrosis, and many other chronic diseases. the lessons that we learned here are the models that we set are hopefully going to be able to extend this technology out to numerous other diseases where patients suffering with those illnesses who will themselves be able to get a one time intervention that will change the course of the rest

what's your take on this for vertex? >> jim owns the name, i think he walked through it great. individual names, i own an abbvie, i sold two weeks before it had this massive run. it's come too far too fast just on rates coming down. jim said he's more of the acquirers. i'm in the same camp as i own abbvie. >> kevin, we have our delivering alpha investor survey. we asked whichof 2023's weakest sectors has the most, most of you believe health care followed by energy. kevin, what's your take on health care in 2024? i know you own merck and j&j. >> i think this survey has it right. we were expecting health care to do well in 2023. it lagged. we have exposure but you're looking for companies with tremendous free cash flow and to bryn's point if they're looking at acquirers there's plenty of potential out there. generally speaking if you look at health care as an underperformer in '23, we expected to do well in 2024. we're happy with our positions for sure. >> so do you believe it's going to be one of the leaders going into 2024, or you just think it will have better performance than

in the case of vertex, this product cash chevy. uh very they perform christopher past 9 gene editing with a actually editing the gene that ordinarily helps regulate you to give it a little bit of production in our bodies. however, the therapy is expensive, links the en, grueling. there are very few medical facilities authorized to perform it even in the us and fewer still in countries like nigeria, which has the largest number of sickle cell patients. so it is going to be a problem for us to be able to roll this out to where the vast majority of patients with this disease live. scientists believe the sickle cell treatment is only the 1st. so what will likely be a wave of gene editing therapies? for cancer, cystic fibrosis, and many other chronic diseases that us lessons that we learn here. the models that we set are hopefully going to be able to extend this technology out to numerous other diseases where patients suffering with those illnesses who will themselves be able to get a one time intervention that will change the course of

in the case of vertex as product cash chevy. very or they perform christopher past 9 gene editing, where they're actually editing the genes that ordinarily helps regulate, give it to open production in our bodies. however, the therapy is expensive. links the n grueling. there are very few medical facilities authorize to perform it either in the us and see were still in countries like nigeria, which has the largest number of sickle cell patients. so it is going to be a problem for us to be able to roll this out to where the vast majority of patients with this disease live, scientist believe the sickle cell treatment is only the 1st. so what will likely be a wave of gene editing therapies? for cancer, cystic fibrosis and many other chronic diseases. the lessons that we learned here are the models that we set are hopefully going to be able to. ringback extend this technology out to numerous other diseases where patients suffering with those illnesses who will themselves be able to get a one time intervention that will change the co

. >> what message does your vertex into the country? -- what message does your verdict send to the country? >> we wanted to see if they were going to answer about what message the verdict since to the country it looks like they were contemplating answering it. shay moss and lady will be as she identified herself, now how -- have the benefit of the verdict in their favor from the lies of rudy giuliani during the 2020 election. turns out that campaign, the lies and the smears about the 2020 election has proven to be rather expensive for mr. giuliani, for mr. murdoch at dews four, and we will see if there are other vertex to come, one can only presume. kaitlyn, what is astounding beyond the abject cruelty and audacity of rudy giuliani, is the fact that he is still sticking by these guys for which there is absolutely no evidence, claiming there will be evidence and it is three years later, there is none. that is the reason we have not seen any. it was looked at by republican officials in georgia. it was looked at by his own department of ju

vertex is $90 million. they can put in the r&d spend.ut the money allocated to the field of work at the moment and where is it necessary to come from? jennifer: it comes from various sources, investors are playing a big role. we are also seeing big input from the government. you might know the national has a major effort through the advanced gene editing in the context of gene and cell therapy. we have other nonprofit organizations that do philanthropic support. the gates foundation comes to mind but there are others that are supporting this. there is a lot of effort and many people appreciate the genome editing to impact many people if we could really figure out how to reduce costs and make these widely available therapies. make them available for people around the world. caroline: back in 2020 the world was in a different place and optimism around leaps and bounds of creativity and technological development and science in particular was very particular. it feels like 2023, all of the oxygen has been dragged out when it comes to ai and

treatment for the blood disorder these two treatments are the first crisper ones to get fda approval vertex fractionally. blue bird was halted for trading, opening down 20%. then it was halted again, again, those shares are below $4. we'll bring you news when it reopens. >>> coming up, this viral video from google is facing new scrutiny are critics ovretieracng or did google go too far? we'll debate, next like your workplace benefits and retirement savings. with voya, considering all your financial choices together can help you make smarter decisions. voya. well planned. well invested. well protected. ♪ (captivating music) ♪ (♪♪) the first law of thermodynamics states that energy cannot be created or destroyed. (♪♪) but it can be passed on to the next generation. (♪♪) >>> welcome back is google caught in a gemi blunder? the company getting called out after acknowledging its ai video was staged, showing a preproduced rendition of the technology the company saying it was intended on the an illustrative depiction. joining me now are my againsts glad to have you here. steve, let's start with wh

i like vertex. i think he could look at vertex. that is a terrific company. and let's not forget that you want to have a diversified portfolio. it is okay to take a look at the stocks. you and i both know. honeywell and maybe you have a stock that is a bit of a flyer, like footlocker. so emphasize the science that he could be in good shape. now we will go to vincent in new york. >> hello, kramer. how are you? >> i'm good. how are you? >> i'm well. >> how much advice and what kind of advice would you give a 26-year-old that has been daytrading for 26 years and looking to do better? >> if your daytrading, it is a full-time occupation. what do you want to do is put money in the return fund and put money in the vanguard s&p 500 fund and keep putting money away every single month. if you made a lot of money, take off some capital and put it in the vanguard account. that is the way i would suggest to do it because i want you to have exposure to the broader market and not just the stocks you are trading. in most cases, the stock of insider buying and heavy shortage

there was an article that said your company aims to be the vertex of cardiovascular disease.t areyour aspirations in this space, and how big is the opportunity? >> vertex is one of those companies that we admire, as well as companies like gilead and others that have built franchises, and ours is a goal to build a franchise in specialty cardiovascular medicine, for which there's no peer right now in the biopharma space, combining the best of specialty pharma with cardiovascular disease, we believe we can build a very valuable business, one that offers high return on investment for shareholders and benefits for patients. this one particular compound that you are referring to, this is the lead amongst now four in our pipeline, and these data that we announced yesterday read very optimistically, we believe, on this biology and our ability to mine it for potential new medicines. >> how many americans suffer from cardiovascular disease and how many could benefit from this drug, and what does this drug do to improve their health? >> so the results we announced yesterday were from a

in the case of vertex, this product cash chevy. uh v v are they perform chris for past 9 gene editing, where they're actually editing the gene that ordinarily helps regulate. give it a little bit introduction in our bodies. however, the therapy is expensive. lengthy and grueling. there are very few medical facilities authorized to perform. it even in the u. s. and few are still in countries like nigeria, which has the largest number of sickle cell patients. so it is going to be a problem for us to be able to roll this out to where the vast majority of patients with this disease live, scientist believe the sickle cell treatment is only the 1st. so what will likely be a wave of gene editing therapies? for cancer, cystic fibrosis and many other chronic diseases. the lessons that we learned here, the models that we set are hopefully going to be able. ready extend this technology out to numerous other diseases where patients suffering with those illnesses who will themselves be able to get a one time intervention that will change the co

so what happened was the company, vertex ancrispr therapeutics, that make this treatment, what they didsive tests saying we are looking and looking to see if this treatment is disrupting other genes. in both cases, it means a lot to have this treatment approved. john: you say not all people with sickle cell would qualify for this. what is the difference? what would make someone ineligible for this? gina: what happens with sickle cell is the red blood cells get deformed and they get caught in red blood vessels and people have frequent episodes of really unbearable pain that send them to emergency rooms looking for opioids and often they are dismissed as drug seeking. they get hospitalized. it is totally debilitating. in order to qualify, you have to have several of these episodes a year. then the other thing that could make somebody ineligible is if their doctor thought they could not tolerate the grueling treatment. first, you have to have eight weeks of transfusions when people are trying to take stem cells, immature cells out of your bone marrow. you have to go to the hospital spend a

for sickle cell disease using gene editing technology known as chris for a therapy developed by the vertex company, uses a patients own cells, removed and modified to produce normally shaped blood cells are, patients will come in they will have their stem cells taken out, they released some of them, they get to keep everything else, but there's the stem cells. some of their stem cells are harvested. those go back to the mat if.

this is their reaction to the vertex earlier today. >> the lies rudy giuliani told about me and my mommy after the 2028 presidential election has changed our lives. in the last few years it has been devastating. the flame that rudy giuliani lit with those lies and passed to so many others to keep that flame blazing changed every aspect of our lives. money will never solve all of my problems. i can never move back into the house that i called home. i will always have to be careful about where i go and who i choose to share my name with. i miss my home. i miss my neighbors. i miss my name. >> two more victims of donald trump selection lies, although they singled out rudy giuliani as being the one who specifically smeared them more so than anyone else. caitlin, it just begs to believe, all of these reputations, all of these lies, all of this damage to the democracy, to individual americans, just because one man could not accept the fact that he lost. >> you know i'm thinking of, she looks different than she did when she had the job in 2020, and that is something she testified. she said she

vertex pharmaceuticals is up by 8%. on positive results on one of its drugs. back to you.his sets us up for the question of the day. when and why will the fed or ecb cut. sophia let's go with the fed. when and why will they cut? >> thank you for having me. when and why. we are waiting to see today what the fed will give us in terms of the insight into their reaction. the when and the y depends on the fed's strategy framework and the data. one thing that's been interesting from the recent fed comments is fed officials have opened the door to easing policy and cutting interest rates potentially before the economy slows and flak opens up significantly in the labor market. these are the things the market is trying to quantify more. that's why today's statement in the press conference will be scrutinized for those clues. guy: good morning. if the fed is cutting because inflation is coming down, doesn't it hold true it can hike again if it goes back up again? i'm wondering if they cut based on inflation is a less sticky cut than one based on the economy that slowing down and a c

some startups approach a foundational model today through openai, anthropic, or google vertex.question will be of the foundational models are going to provide use case specific or injured street -- or industry-specific -- ed: you started in 2003 in ad sales. everyone that i spoke to at that time said that we were kicking around a hakki sack talking about ai and the big picture way. dan: i think that the case is when you're talking about the biggest opportunities and contact center and sales organizations to say that we can provide instant -- the availability to instantly confirm, satisfaction. we can note take a system of record. those are things that every business on the planet in sales and support struggle with. caroline: we thank you for some of those insights. looking back on the past 12 months, looking forward. coming up, what is happening, backing her boss after his insults to brands backing away from the platform. details coming next. dear moms and dads, what you have achieved here today is going to help us and our futures. it is why we're coming up on stage to collect

this is something that, you know, just got with vertex pharmaceuticals, just got the nod to treat sicklel apeople -- anemia. it's an affliction that has almost no treatment possibilities. so this has the potential to change the world. they have also oncology potential, they have potential to treat lupus, really difficult to treat drugs and getting fda approval. this has been a huge investment for decades. it's starting to come to the fore, as something that has block buster potential. so, you know, we think that this kind of a name is something that really doesn't matter what happens in the economy, these, you know, these drugs are going to be hugely beneficial and in demand. >> all right. gina sanchez with the stock list as crisper therapeutics, abvie and auto home, as well. thank you very much. happy holidays. >>> coming up, three more names on deck with results out. you see them right there. our trader is a buyer of two of the thames that you see on your screen. one for a very specific reason. earnings exchange is coming your way leather on the show. as we head to break, bitcoin price

. >> we could take a look at vertex shares today up 35% on the year and up. a lot coming today, 11%. >> vx 548, to treat chronic nerve pain surrounding diabetes. this company is trying to diversify, known for its treatment of cystic fibrosis, is reasonably valued, very strong momentum in place. it's a stock that has been in the quality momentum etf since april of 2022. i think it continues to march higher. >> all right, bryn, what do you want to make of the tesla recall, 2 million vehicles? it's a lot. the stock is down near 3%. you own it. what's your read on it? >> when the apple 15 came out and started overheating, did we go out and say that apple was doing a recall of the apple 15? no. they did a software update, yet everyone is, like, freaking out because tesla is going to recall, putting in quotes, 2 million cars, when in reality they've already done or are about to do a software update. i think this is a great example of what car company in the history of the world has ever had to do something to 2 million cars and they can do a simple software update.

vertex is the largest holding in the ibb. that stock has been parabolic. trying to find stocks, i think, that haven't had to move. steve mentioned amgen and i throw qb in the mix. >> the severe underweighting towards biotech, where are you? >> i do think that it is likely going to be another category that will benefit from lower interest rates. especially it's going to have more m&a. you want to look at companies where the patent expiring is going to be a big deal for a lot of these companies so even if they are scooping up other firms, it needs more than to offset what they're losing. that's what you keep an eye on. >> we talked about pfizer. i've talked about it. a patent cliff and pipelines that people are concerned about. bristol myers is rewarded for doing something. they're right if that camp and you have to be careful about value traps in health care. trades at 7 1/2 next year. analysts think this is part of them giving the excitement around pipeline that gets them into 2030. that's a ways out. so this is where we are. biotech, great point, courtney

the first is the -- is vertex pharmaceuticals.the first gene editing treatment approved here in the u.s. the second from bluebird bio that drug was expected to be approved later this month. this is coming a little earlier than expected. shares of bluebird are halted right now based on this news, but this is a big day for people with sickle cell disease that's a rare genetic blood disorder we'll be back with more as we hear about the prices of these drugs and more details carl >> angelica, thank you pretty fascinating. >>> still to come this morning, big tech may be cracking the code a new key bank report outlines the changing on streaming and who stands to benefit the most we'll break that down. >>> watching honeywell, they will buy carrier global for $5 billion on cash. the ceo talked on "squawk on the street" earlier today. >> we will constantly look at improving the portfolio quality through m&a. that's our strategy. m&a is our strategy. any time you bring in an asset, we look at i ht,ow it grows the core business but also adds

other states can have different roles about vertex.ia's repugnance he ruled if anything is the most sensible way to responding to a rare set of circumstances, generally a pro-defendant rule that ensures the parties obtain accurate critical facts. e itical factor of mcelrath 's sanity was not determined here. therefore he can be reie i welcome court questions. >> if you only had one charge here, malice murder, erthere have been a verdict? >> that depends on athe jury comes back with. >>vething is the same except it's one charge. >> you would have a verdict. if this constitutes a verdict, if there re only one, why does it n cstitute a verdict when there are two? georg ds not ascribe to the legal fiction the jy finding different facts when okg at the exact same --. >> you have a verdict. you say that if if it is only malice murder, then you would have a verdict here. >> yes. ifhat was all that was in the case, the on tng going on. >> does everything -- is everything in the case is exactly the same except there is only one charge. >>es >>

vertex says their pain pill has succeeded in a stage two twiel.nerve pain that people with diabetes has developed. they're studying the pill while we're expecting rulgts from that early next year. stocks are up 2% premarket. this is something investors have been really excited about. this is such a big opportunity. there's so much excitement and so much need for a nonopioid pain pill. >> the reason for that, it's not addictive. it's a much safer situation? >> that's the idea. of course, that needs to be proven out, but the science suggests this would not be addictive. it works differently. it doesn't work in the brain like the opioids do hopefully it will provide some of that same relief. >> when you say it has to be proven out, that's what it's designed to do? >> it will look at how efficacious it is. i don't know how they man to look at whether it ee addictive or not. again, the skriep activities don't think it should be addictive. >> do you know what the mechanism is? >> it's called a sodium channel blocker. that's where the pain signals run th

verte ve vertex pharma a top gainer.vehicle it sold in the u.s., nearly 2 million cars. a two-year investigation found deficiencies in its auto pilot system. although the term recall is contested sometimes. >> yeah. it's used as a term of art but it doesn't mean you're taking your car to the dealership of any kind it's an over-the-air software upgrade they'll deal with. >> meanwhile a lot of sign posts to look at this morning the. >> ppi read on wholesale inflation following the trend we've seen lately from ppi pretty benign, just more evidence that inflation is cooling, good news for the fed. of course today is fed day and we will get that decision, that statement, that press conference and the summary of economic projections, but there's the ppi look, year over year, it's pretty much -- it's less than a percent higher, flat on the month. and core ppi, which strips out food and energy prices at the wholesale level also very benign. good for the fed. what are we watching today? signals that the fed is still in the tighte

but david, as great as this is, the stock that people keep talking about is vertex, because if you havese habit forming behavior, then you have to buy the stock. it's coming down so it's an opportunity. >> it was up yesterday. of course, we discussed it, the positive phase two trial, i believe. >> they publicized that, which means their confidence level is high. >> that conaceivably would replace opioids. we're in the midst of an absolute crisis in the country. we don't talk about that often. >> why don't we? it's at the core of a lot of the problems with employment, health care, and we don't talk about it enough. >> 300 people a day dying of opioid or opioid related -- >> if you had something, you could change whole towns. >> got a record high on apple, jim. 199.62. citi today named it a top pick for '24. the bears are missing iphone premiumization, the silicon sources, they think vision pro and ai is just an upside catalyst. >> look, i have to tell you, i think -- i thought that report was very good in terms of talking about the service revenue. they're using 16%. i think they're low

s&p 500 winners, vertex, take two interactive, albemarle, emerson electric.ers, show me a big name tech stock. they're not there. but airbnb is up there, astrazeneca, marvell technology. where's the 10-year? it is down this morning, 4.15%. that does help big tech and the nasdaq. the price of gold, below $2,000 an ounce, $1998. check bitcoin, 41 and change last time we checked it, 41,3 right now. oil, well below $70 a barrel, you're all the way down to 68.8ing 6. nat gas? up, down or sideways? show me, please. it is down this morning a tiny fraction. >>> i'm intrigued at the price of gasoline, it chemos on coming down -- it keeps on coming down. you're at $3.12 for the national average, and diesel down as well, $4.07. >>> florida attorney general ashley moody fed up with shoplifters. she launched a statewide task force to combat organized retail crime. she's going to tell us what she's going to do. >>> lebron james taking heat for what he was doing at his son's basketball game. critics say he has no respect for americaful we'll tell you what he did. >>> the co